Method for Replicating Influenza Virus in Culture
OwnerTerri L. Wasmoen, Peng Gao +2inventors
InventorsTerri L. Wasmoen, Peng Gao, Bradley Allen Eddy, Omar Yousif Abdelmagid
Life of this patent
Estimating the term…
Abstract
The invention is related to a method for selecting an influenza virus for growth on tissue culture cells to produce a tissue-culture adapted viral isolate. The invention also includes vaccines produced from the isolate.
Claims35
A method of selecting a human influenza virus for growth on tissue culture cells by limiting dilution cloning, the method comprising:
- serially diluting an influenza virus isolate and
- contacting each dilution with cultured cells:
- growing the cells for a time sufficient to produce cytopathic effects (CPE);
- harvesting virus from the highest dilution that causes CPE;
- and
- repeating the process with the harvested virus.
An immunogenic composition comprising a BEI-inactivated human influenza virus and an adjuvant.
A vaccine comprising a human influenza virus formulated at less than 4 μg of human influenza HA per dose wherein at least 70% of the HA has the same amino acid sequence.
A method of selecting a canine influenza virus (CIV) H3N8 for growth on tissue culture cells by limiting dilution cloning, the method comprising:
- serially diluting an influenza virus isolate and
- contacting each dilution with cultured cells;
- growing the cells for a time sufficient to produce cytopathic effects (CPE);
- harvesting virus from the highest dilution that causes CPE;
- and
- repeating the process with the harvested virus.
An immunogenic composition comprising an inactivated canine influenza virus (CIV) H3N8 and an adjuvant.
The vaccine of claim 34, wherein at least 90% of the HA has the same amino acid sequence.
Dependencies are inferred from the claim text.